153 related articles for article (PubMed ID: 36896730)
1. Visible Light Conjugation with Triazolinediones as a Route to Degradable Poly(ethylene glycol)-Lipids for mRNA Lipid Nanoparticle Formulation.
Golba B; Soete M; Zhong Z; Sanders N; Du Prez FE; Houck HA; De Geest BG
Angew Chem Int Ed Engl; 2023 Jun; 62(23):e202301102. PubMed ID: 36896730
[TBL] [Abstract][Full Text] [Related]
2. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
3. Fluorinated Lipid Nanoparticles for Enhancing mRNA Delivery Efficiency.
Zhang H; Meng C; Yi X; Han J; Wang J; Liu F; Ling Q; Li H; Gu Z
ACS Nano; 2024 Mar; 18(11):7825-7836. PubMed ID: 38452271
[TBL] [Abstract][Full Text] [Related]
4. PEG-OligoRNA Hybridization of mRNA for Developing Sterically Stable Lipid Nanoparticles toward In Vivo Administration.
Kurimoto S; Yoshinaga N; Igarashi K; Matsumoto Y; Cabral H; Uchida S
Molecules; 2019 Apr; 24(7):. PubMed ID: 30987102
[TBL] [Abstract][Full Text] [Related]
5. Substituting Poly(ethylene glycol) Lipids with Poly(2-ethyl-2-oxazoline) Lipids Improves Lipid Nanoparticle Repeat Dosing.
Sanchez AJDS; Loughrey D; Echeverri ES; Huayamares SG; Radmand A; Paunovska K; Hatit M; Tiegreen KE; Santangelo PJ; Dahlman JE
Adv Healthc Mater; 2024 Feb; ():e2304033. PubMed ID: 38318754
[TBL] [Abstract][Full Text] [Related]
6. Tailored Monoacyl Poly(2-oxazoline)- and Poly(2-oxazine)-Lipids as PEG-Lipid Alternatives for Stabilization and Delivery of mRNA-Lipid Nanoparticles.
He X; Payne TJ; Takanashi A; Fang Y; Kerai SD; Morrow JP; Al-Wassiti H; Pouton CW; Kempe K
Biomacromolecules; 2024 Jun; ():. PubMed ID: 38918933
[TBL] [Abstract][Full Text] [Related]
7. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury.
Waggoner LE; Miyasaki KF; Kwon EJ
Biomater Sci; 2023 Jun; 11(12):4238-4253. PubMed ID: 36987922
[TBL] [Abstract][Full Text] [Related]
8. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
9. Lipid nanoparticles for local delivery of mRNA to the respiratory tract: Effect of PEG-lipid content and administration route.
Ongun M; Lokras AG; Baghel S; Shi Z; Schmidt ST; Franzyk H; Rades T; Sebastiani F; Thakur A; Foged C
Eur J Pharm Biopharm; 2024 May; 198():114266. PubMed ID: 38499255
[TBL] [Abstract][Full Text] [Related]
10. Lipid nanoparticles containing labile PEG-lipids transfect primary human skin cells more efficiently in the presence of apoE.
Gregersen CH; Mearraoui R; Søgaard PP; Clergeaud G; Petersson K; Urquhart AJ; Simonsen JB
Eur J Pharm Biopharm; 2024 Apr; 197():114219. PubMed ID: 38368913
[TBL] [Abstract][Full Text] [Related]
11. Hydrophobic Domain Structure of Linear-Dendritic Poly(ethylene glycol) Lipids Affects RNA Delivery of Lipid Nanoparticles.
Zhou K; Johnson LT; Xiong H; Barrios S; Minnig JT; Yan Y; Abram B; Yu X; Siegwart DJ
Mol Pharm; 2020 May; 17(5):1575-1585. PubMed ID: 32267707
[TBL] [Abstract][Full Text] [Related]
12. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
13. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs.
Lokugamage MP; Vanover D; Beyersdorf J; Hatit MZC; Rotolo L; Echeverri ES; Peck HE; Ni H; Yoon JK; Kim Y; Santangelo PJ; Dahlman JE
Nat Biomed Eng; 2021 Sep; 5(9):1059-1068. PubMed ID: 34616046
[TBL] [Abstract][Full Text] [Related]
14. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
Sakurai Y; Mizumura W; Ito K; Iwasaki K; Katoh T; Goto Y; Suga H; Harashima H
Mol Pharm; 2020 Apr; 17(4):1397-1404. PubMed ID: 32091909
[TBL] [Abstract][Full Text] [Related]
15. Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina.
Gautam M; Jozic A; Su GL; Herrera-Barrera M; Curtis A; Arrizabalaga S; Tschetter W; Ryals RC; Sahay G
Nat Commun; 2023 Oct; 14(1):6468. PubMed ID: 37833442
[TBL] [Abstract][Full Text] [Related]
16. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production.
Suzuki T; Suzuki Y; Hihara T; Kubara K; Kondo K; Hyodo K; Yamazaki K; Ishida T; Ishihara H
Int J Pharm; 2020 Oct; 588():119792. PubMed ID: 32827675
[TBL] [Abstract][Full Text] [Related]
17. Elucidation of lipid nanoparticle surface structure in mRNA vaccines.
Wang MM; Wappelhorst CN; Jensen EL; Chi YT; Rouse JC; Zou Q
Sci Rep; 2023 Oct; 13(1):16744. PubMed ID: 37798336
[TBL] [Abstract][Full Text] [Related]
18. Optimization of a Degradable Polymer-Lipid Nanoparticle for Potent Systemic Delivery of mRNA to the Lung Endothelium and Immune Cells.
Kaczmarek JC; Kauffman KJ; Fenton OS; Sadtler K; Patel AK; Heartlein MW; DeRosa F; Anderson DG
Nano Lett; 2018 Oct; 18(10):6449-6454. PubMed ID: 30211557
[TBL] [Abstract][Full Text] [Related]
19. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles.
Yanez Arteta M; Kjellman T; Bartesaghi S; Wallin S; Wu X; Kvist AJ; Dabkowska A; Székely N; Radulescu A; Bergenholtz J; Lindfors L
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3351-E3360. PubMed ID: 29588418
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of linear and cyclic peptide-PEG-lipids for stabilization and targeting of cationic liposome-DNA complexes.
Ewert KK; Kotamraju VR; Majzoub RN; Steffes VM; Wonder EA; Teesalu T; Ruoslahti E; Safinya CR
Bioorg Med Chem Lett; 2016 Mar; 26(6):1618-1623. PubMed ID: 26874401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
